Key result
Cilostazol treatment for 7 days before ischemia significantly suppressed the risk and severity of cerebral hemorrhage after tPA injection in a murine stroke model compared to aspirin or no treatment.
Why the study?
Does cilostazol reduce the risk of cerebral hemorrhage after tissue-type plasminogen activator administration in a murine stroke model?
Population
Murine stroke model (mice subjected to a highly reproducible transient ischemia model)
Comparison
Cilostazol for 7 days before ischemia, followed… vs Aspirin or no treatment, followed by tissue-type…
Design
Preclinical
Authors
Loading...
May support cilostazol pre-treatment to reduce tPA hemorrhage; hypothesis-generating in animals, no practice change yet.
Does cilostazol reduce the risk of cerebral hemorrhage after tissue-type plasminogen activator administration in a murine stroke model?
Pre-treatment with cilostazol, but not aspirin, reduces the risk and severity of tPA-induced cerebral hemorrhage in a murine stroke model, suggesting a potential strategy to improve the safety of thrombolytic therapy.
Kasahara et al. (2011) studied Stroke. Cilostazol vs. Aspirin or no treatment was evaluated on Risk and severity of cerebral hemorrhage. Cilostazol treatment for 7 days before ischemia significantly suppressed the risk and severity of cerebral hemorrhage after tPA injection in a murine stroke model compared to aspirin or no treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: